Sunesis Pharmaceuticals (SNSS) versus Its Rivals Critical Contrast
Sunesis Pharmaceuticals (NASDAQ: SNSS) is one of 187 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Sunesis Pharmaceuticals to similar businesses based on the strength of its valuation, profitability, institutional ownership, earnings, risk, analyst recommendations and dividends.
This is a summary of recent ratings and target prices for Sunesis Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sunesis Pharmaceuticals Competitors||537||2445||6617||123||2.65|
Volatility and Risk
Sunesis Pharmaceuticals has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Sunesis Pharmaceuticals’ competitors have a beta of 1.57, meaning that their average share price is 57% more volatile than the S&P 500.
Earnings and Valuation
This table compares Sunesis Pharmaceuticals and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Sunesis Pharmaceuticals||$2.54 million||-$38.02 million||-1.30|
|Sunesis Pharmaceuticals Competitors||$217.29 million||-$39.39 million||-69.89|
Sunesis Pharmaceuticals’ competitors have higher revenue, but lower earnings than Sunesis Pharmaceuticals. Sunesis Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Sunesis Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sunesis Pharmaceuticals Competitors||-3,317.69%||-533.08%||-39.74%|
Institutional and Insider Ownership
38.4% of Sunesis Pharmaceuticals shares are held by institutional investors. Comparatively, 48.0% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 10.2% of Sunesis Pharmaceuticals shares are held by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Sunesis Pharmaceuticals competitors beat Sunesis Pharmaceuticals on 8 of the 12 factors compared.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.